Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • IR
  • All Products
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • IR
  • All Products
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR
  • Sign Up
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media Enquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • my CNW
  • GDPR

Public Advisory - Unauthorized drugs seized from Rabais 4Saisons Inc. in Montreal, QC, may pose serious health risks

Français

News provided by

Health Canada (HC)

Aug 18, 2026, 15:15 ET

Share this article

Share toX

Share this article

Share toX

OTTAWA, ON, Aug. 18, 2026 /CNW/ --

Summary

After-D (Levonorgestrel 1.5mg)
After-D (Levonorgestrel 1.5mg)
Albendazol 200mg.5mL
Albendazol 200mg.5mL
Balaxi - Amoxicilline 500mg
Balaxi - Amoxicilline 500mg
Balaxi - Tetracycline 500mg
Balaxi - Tetracycline 500mg
Black Horse - Vital Honey
Black Horse - Vital Honey
Caplin Point - Ampicillin 500mg
Caplin Point - Ampicillin 500mg
Erix - 100mg (Unichem)
Erix - 100mg (Unichem)
Saad - Ampicillin 500mg
Saad - Ampicillin 500mg
After-D (Levonorgestrel 1.5mg) Albendazol 200mg.5mL Balaxi - Amoxicilline 500mg Balaxi - Tetracycline 500mg Black Horse - Vital Honey Caplin Point - Ampicillin 500mg Erix - 100mg (Unichem) Saad - Ampicillin 500mg
  • Product: Various unauthorized health products, including prescription drugs
  • Issue: Health products – unauthorized products
  • What to do: Do not buy or use unauthorized health products. Consult a licensed healthcare professional (physician, nurse practitioner, pharmacist) if you have used these products and have health concerns.

Photos

Affected products

Product

Prescription drug

After-D

Labelled to contain levonorgestrel

Albendazol

Labelled to contain albendazole

Balaxi – Amoxicilina

Labelled to contain amoxicillin

Balaxi – Tetraciclina

Labelled to contain tetracycline

Black Horse Vital Honey

Product with similar packaging (previously seized) was tested and found to contain sildenafil

Caplin Point

Labelled to contain ampicillin

Erix

Labelled to contain sildenafil

Saad – Ampicilina

Labelled to contain ampicillin

Issue
Health Canada has seized several unauthorized drugs (including an oral emergency contraceptive drug, erectile dysfunction drugs, and antibiotic and antiparasitic drugs) from Rabais 4Saisons Inc. (5321 rue de Charleroi), in Montreal, Quebec, because they may pose serious health risks.

Selling unauthorized health products in Canada is illegal. Unauthorized health products have not been approved by Health Canada, which means they have not been assessed for safety, effectiveness and quality and may pose serious health risks. For example, they may lack active ingredients, vary in their concentration or contain ingredients, additives or contaminated ingredients not listed on the label that could interact with other medications and foods.

Many of the seized products are unauthorized versions of prescription drugs available in Canada. Prescription drugs should be used only under the supervision of a health care professional because they are used to treat specific conditions and may cause serious side effects. Several of the products are not labelled in English and French as required in Canada. As a result, information about ingredients, usage, dosage and side effects may not be available to or understood by consumers.

Health Canada acts to protect public health and safety when companies are found to be selling unauthorized health products in Canada, including warning consumers when warranted. The Department also works with the Canada Border Services Agency to help prevent the import of any unauthorized health products. 

What you should do

  • Do not buy or use unauthorized health products.
  • Consult with a licensed healthcare professional (physician, nurse practitioner, pharmacist) if you have used these products and have health concerns.
  • Check if your health products are authorized. Authorized health products have an eight-digit Drug Identification Number (DIN), Natural Product Number (NPN) or Homeopathic Drug Number (DIN-HM). You can also check whether products are authorized for sale by searching Health Canada's Drug Product Database or Licensed Natural Health Products Database.
  • Report any health product-related side effects or complaints to Health Canada.

Background

Albendazole is not currently approved for human use in Canada, but is authorized as a prescription drug in other countries. It is used to treat severe tapeworm infections in the brain, liver, or lungs and carries several serious health risks that require strict medical monitoring. It can cause dangerous drops in blood cells (bone marrow suppression) and liver damage, both of which can be fatal if untreated. It can also cause severe harm to a fetus, so it should not be used during pregnancy. Additionally, its antiparasitic action in the brain can trigger sudden neurological issues like seizures, severe headaches, or vision problems, requiring a pre-treatment eye exam and potentially other treatments to manage brain swelling. Allergic symptoms may include severe painful skin rashes that blister or peel. Common, less severe side effects include headaches, nausea, dizziness, stomach pain, and temporary hair loss.

Amoxicillin and ampicillin are prescription antibiotic drugs used to treat certain bacterial infections. They should be used only under the supervision of a health care professional. Ampicillin and amoxicillin may cause severe life-threatening allergic reactions. In rare cases, these allergic reactions can cause severe chest pain or even trigger a heart attack. Allergic symptoms may also include swollen lips, face, throat, difficulty breathing, severe painful skin rashes that blister or peel, itchiness, nausea, vomiting, diarrhea, and signs of kidney and liver failure. They should not be used by patients with known allergies to these drugs. Patients with allergies to other antibiotic types may also experience allergic reactions to ampicillin and amoxicillin. These drugs can also interact with other prescription medications, such as certain blood thinners, cancer therapies, or birth control pills. Misuse or overuse could lead to growth of bacteria that will not be killed by ampicillin and amoxicillin and means that they may not work in the future when required (this is known as antibiotic resistance).

Levonorgestrel is a non-prescription drug used as an emergency contraceptive to prevent pregnancy within 72 hours of known or suspected contraceptive failure or unprotected sex, when sold as a single ingredient oral dose containing no more than 1.5 milligrams. Unauthorized emergency contraceptives labelled to contain levonorgestrel may not be effective and may not prevent pregnancy as expected. The drug should not be taken by those allergic to levonorgestrel, or by those who are, or who suspect they are pregnant. For patients with undiagnosed abnormal vaginal bleeding, a pregnancy test should be performed before taking levonorgestrel. Levonorgestrel as an emergency contraceptive prevents pregnancy; it does not induce abortion and should not be taken by pregnant women as it will not be effective. Levonorgestrel is intended for emergency use and should not be used as a regular method of birth control, and if used more than once, the overall chance of pregnancy may increase. There are authorized levonorgestrel emergency contraceptive products available in Canada. 

Sildenafil is a prescription drug used to treat erectile dysfunction and should be used only under the supervision of a health care professional. It should not be used by people who are allergic to sildenafil. It should also not be used by individuals taking any kind of nitrate drug (e.g. nitroglycerine) as it can cause potentially life-threatening low blood pressure. Individuals with heart problems are at increased risk of cardiovascular side effects such as heart attack, stroke, chest pain, high blood pressure and abnormal heartbeat. Other possible side effects include headache, facial flushing, indigestion, dizziness, abnormal vision, and hearing loss. Additionally, individuals who are over 65 years of age, or with liver impairment or severe kidney impairment, or who are also taking certain medications (e.g. erythromycin, saquinavir, ritonavir), are at an increased risk of side effects.  

Tetracycline is a prescription antibiotic drug used to treat certain bacterial infections. It should be used only under the supervision of a health care professional. It should not be used by people who are allergic to tetracycline or similar drugs, or who have severe kidney or liver disease. An allergic reaction can be life-threatening, causing sudden swelling of the face, lips, tongue, or throat, and severe breathing failure. It should not be used during pregnancy, as it could cause teeth and bone changes in the fetus and serious liver damage in the mother. Tetracycline can reduce the effect of birth control pills. It should not be used by patients who are breastfeeding as tetracycline passes into breast milk and can cause tooth discolouration in the baby. Tetracycline should not be used in children under 12 years of age, as it can affect bone and cause permanent tooth discolouration. Exposure to sunlight or ultraviolet light (e.g., sunlamps) should be avoided when taking tetracycline as the drug can increase skin sensitivity and cause severe sunburn. Because tetracycline alters natural stomach bacteria, it can cause a severe, life-threatening bowel infection resulting in violent diarrhea. Ingesting expired or deteriorated tetracycline pills can cause severe, irreversible kidney damage that can result in death. Tetracycline might interact with other medications and cause serious adverse reactions. Misuse or overuse could lead to growth of bacteria that will not be killed by tetracycline and means that it may not work in the future when required (this is known as antibiotic resistance).

Également disponible en français

SOURCE Health Canada (HC)

Media Enquiries: Health Canada, (613) 957-2983, [email protected]; Public Enquiries: (613) 957-2991, 1-866 225-0709, [email protected]

Modal title

Organization Profile

Health Canada (HC)

    Also from this source

  • Notice to the media - Government of Canada to make an announcement in support of youth mental health in the Yukon

  • Public Advisory - Two lots of Teva-Pregabalin 150 mg capsules recalled due to cross-contamination with the drug sertraline

  • Public Advisory - Unauthorized injectable health products sold online and seized from Dyosa Beauty & Wellness Lounge in Hamilton, ON, may pose serious health risks

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • Investor Relations

About

  • About PR Newswire
  • About Cision
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Platform Login
  • Privacy Policy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.